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ABSTRACT 
Background: Atrial fibrillation (AF) is the most commonly diagnosed arrhythmia, which is 
associated with an increased risk of stroke. Several studies have suggested that female 
AF patients could have a greater risk for stroke and thromboembolic events (TE).  
Methods: A systematic literature review update and meta-analysis was conducted using 
Pubmed. The search used the terms “atrial fibrillation”, “gender”, “sex”, “female”, “women”, 
“stroke”, “thromboembolism”. Main aim of the study was to compare and male AF patients 
for occurrence of stroke and TE. Secondary outcomes were: major bleeding, 
cardiovascular (CV) death and all-cause death.   
Results: Forty-four studies were included in the analysis including 993,603 patients 
(48.9% women). After pooling the data, there was a higher risk of stroke for women vs. 
male AF patients (hazard ratio [HR]:1.24; 95% confidence intervals [CI]:1.14-1.36]. 
Overall, TE risk was not different between female and male patients, despite sensitivity 
analysis left some uncertainties. No sex differences were found for major bleeding, CV 
death and all-cause death. A significant relationship between increasing age and the 
difference in stroke risk between female and male AF patients was found (Delta HR:1.01; 
95% CI:1.00-1.03 for each year of age increase).   
Conclusions Female patients with AF are at increased risk of stroke compared to men.  A 
significant relationship between increasing age and stroke risk in women compared to men 
was found, most evident at age >65 years. Female sex may act as a stroke risk modifier, 
particularly in elderly and very elderly AF subjects, conferring a significant increase in 
stroke risk. 
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1. INTRODUCTION 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, which is 
associated with a five-fold increase in risk of stroke and thromboembolic events (TE).  This 
increased risk is not homogeneous and depends on the presence of various stroke risk 
factors[1].  
 
Despite a higher reported prevalence of AF in male subjects[2], several studies have 
described an increased risk for stroke and cerebrovascular events in women than in men, 
especially in older patients age ≥75 years old[3]. Indeed, female sex has been included as 
a risk factor in clinical risk prediction scores for stroke/TE risk stratification[4]. 
Nevertheless, the increased risk of stroke/TE in women compared to men has a 
dependency on age and risk factors, such that no excess of stroke risk is evident in female 
AF patients age <65 or without other risk factors present[1].  Thus, female sex may be a 
“stroke risk modifier”, rather than an actual risk factor per se[5]. 
 
Several possible mechanisms have been proposed to explain a sex difference in stroke 
risk:  for example, female sex hormones can favour the occurrence of thrombosis 
modulating pro-coagulant proteins’ levels, platelet and endothelial functions[6]. Moreover, 
stroke severity, functional outcomes and quality of life are poorer in female than in male 
patients after occurrence of stroke[7,8]. Significant differences in the medical management 
of female AF patients, which may partly explain their increased risk of stroke[9].  Also, 
female AF patients tend to be undertreated and given less appropriate 
thromboprophylaxis[10]. 
 
The aim of this paper is to provide an updated systematic review and meta-analysis of 
available evidence regarding the differences in stroke and TE between female and male 
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AF patients. Second, we will investigate sex differences among AF patients in the risk of 
other major adverse events (major bleeding, cardiovascular (CV) death and all-cause 
death). 
 
2. METHODS 
The present systematic review and meta-analysis was performed according to PRISMA 
recommendations (http://www.prisma-statement.org/).   
 
2.1 Data Sources and Searches 
We planned an update of the systematic review published by Cheng and colleagues[9]. 
The original paper included all manuscripts published up until 2014. We then performed a 
comprehensive literature search using PubMed database from 01st January 2015 up to 
19th May 2017. According to the original review, the search was performed using the terms 
“atrial fibrillation”, “gender”, “sex”, “female”, “women”, “stroke”, “thromboembolism”. The full 
search strategy is reported in the Supplementary Material. 
 
2.2 Studies Selection 
According to the original systematic review, studies were included in this systematic review 
if data about stroke and/or thromboembolic events stratified by sex were reported. Two co-
authors (GFR and IR) independently screened the search results. Disagreements were 
resolved by collegial discussion. All articles retrieved from the search were evaluated 
according to titles (mostly excluding non-original data papers, commentaries, viewpoints 
and all entries that clearly did not qualify for inclusion) and abstracts sequentially. Other 
exclusion criteria were: i) conference abstracts, letters, comments, case reports, editorials; 
and ii) studies not published in English. 
 
ACCEPTED MANUSCRIPT
AC
C
EP
TE
D
 M
AN
U
SC
R
IP
T
 
 
 
7 
Subsequently, evaluation of full text eligibility was performed independently by two co-
authors (IM and MP). Disagreements were resolved by collegial discussion. All full texts, 
as well as the 30 articles retrieved from the original systematic review, were assessed for 
meta-analysis eligibility according to the following criteria: i) all studies reporting about at 
least 1-year of follow-up observation; and ii) all studies providing enough details to obtain 
number of events, incidence rates or measures of effect according to sex to be included in 
the meta-analysis process.  
 
2.3 Data Extraction and Quality Assessment 
Data were extracted independently by two co-authors (IM and MP). All data on sample 
size and sex subgroups, number of events, incidence rates or measures of effect were 
collected. Data about year of study, geographical location and cohort type, age, use of oral 
anticoagulant (OAC) drugs and follow-up time were also collected. Year of study was 
categorized as follows: i) 1999-2012; ii) 2013-2015; iii) 2016-2017. Main outcomes 
considered were stroke and/or TEE. Additionally, data on major bleeding, cardiovascular 
(CV) death or all-cause death were collected, where available. 
 
All studies were evaluated for the risk of bias by two co-authors (GFR and IR), according 
to recommendations of the Agency for Healthcare Research and Quality[11], specifically 
selection, performance, attrition, detection and reporting bias. A publication bias 
assessment was performed as reported below. 
 
2.4 Data Synthesis and Analysis 
For each study, hazard ratios and their standard errors were either extracted or computed 
on the basis of available information. Choice between fixed and random effects meta-
analysis was performed on the basis of the I2 index, where I2 > 25% lead us to conduct 
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8 
random effects meta-analyses based on linear (mixed-effects) models with inverse-
variance weights. A similar approach has been used for the meta-regression. We 
considered some study specific characteristics as continuous predictors (female 
prevalence, mean age of the sample, OAC prevalence, maximum follow-up time), while 
other characteristics were considered as categorical predictors (publication year in three 
classes [1999-2012, 2013-2015, 2016-2017], type of study [randomized controlled trial 
(RCT), Insurance Database, Observational Study, Population Cohort] and geographic 
location [Europe, Middle East/Asia, North America, Multinational]. Further to the meta-
regression, we reported subgroup analyses according to the categorical predictors. 
 
Publication bias was assessed by means of funnel plots and regression tests for funnel 
plot asymmetry. Sensitivity analysis was conducted by removing one study at a time and 
comparing the resulting meta-analysis with the complete one. All analyses have been 
performed using R Statistical Package Software version 3.3.3 (R Foundation). 
 
3. RESULTS 
After the electronic search, a total of 2157 results were retrieved. After screening 
procedure, 61 full-texts were assessed for eligibility, with 43 papers excluded [Figure S1]. 
Further, the 30 articles included in the original systematic review[9] were assessed for 
eligibility, with 4 records excluded [Figure S1]. A total of 44 papers were finally included in 
the present systematic review and meta-analysis (Table 1)[12–55].  
Overall, seven studies were derived from RCTs, 18 observational studies, 16 population 
cohort studies and 4 insurance database studies. Prevalence of female sex was largely 
variable across the studies included with a mean (SD) of 41.9% (8.7%), with the lowest 
prevalence (20.4%) reported by Boriani et al.[37] and the highest (55.2%) reported by 
Shanta and colleagues[49] [Figure S2]. 
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3.1 Overview of Included Studies 
In the study by Friberg et al., including 100802 patients discharged for AF, stroke occurred 
more commonly in women than in men[17]. After stratification by CHADS2 score the 
increased risk of stroke in women was still evident across all strata. In the multivariable 
analysis the association between ischemic stroke and female sex was still significant 
(hazard ratio [HR]: 1.18; 95% confidence interval [CI]: 1.12-1.24)[17]. 
 
Similar results were observed in another retrospective observational study on 39398 men 
and 44115 women ≥65 years old discharged from Quebec hospitals with a diagnosis of 
AF[15]. The higher risk of stroke in women compared to men was particularly evident in 
very old patients (≥75 years old). The adjusted risk of stroke in women was HR: 1.14 (95% 
CI: 1.07-1.22); this significant difference was observed irrespective of previous stroke 
history, with women without a previous stroke still reporting a higher risk compared to men 
(HR: 1.17; 95% CI: 1.09-1.23)[15]. Conversely, the unadjusted mortality rates were higher 
in men. Similar results were also seen when patients were stratified according to OAC 
adherence[15]. 
 
In a secondary analysis of the “Apixaban for Reduction in Stroke and Other 
Thromboembolic Events in Atrial Fibrillation” (ARISTOTLE) trial, the total number of 
patients included was 18201, with 35.2% (6416) being women[36]. Women were older 
than men and reported a higher CHA2DS2-VASc score. Risk of stroke was similar in 
women and men; however, the risk of all cause death (HR: 0.63; 95% CI: 0.55-0.73) or 
cardiovascular death (HR: 0.62; 95% CI: 0.51-0.75) was lower in women compared to 
men[36]. 
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10 
In the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) 
registry, female AF patients were found to have more symptoms (like palpitations, light-
headedness, dizziness, fatigue and chest discomfort) compared to male ones, with an 
overall worse quality of life (adjusted quality of life 24% lower in women than in men), 
despite being less likely in persistent and permanent AF[39]. Treatment with antiarrhythmic 
drugs or oral anticoagulant were no different between men and women. The observed 
rates of cardiovascular death and all-cause death were similar between sexes, but after 
adjustment, the risk was significantly lower in women compared to men (HR: 0.56; 95% CI: 
0.44-0.72 and HR: 0.57; 95% CI: 0.49-0.67, respectively)[39]. Female AF patients were at 
higher risk of stroke than men, after adjustment (HR: 1.39; 95% CI: 1.05-1.84)[39]. 
 
In the Far East population, the results are less consistent. In the paper by Yang and 
colleagues, reporting about 2016 Chinese AF patients admitted to emergency room due to 
AF presence, female sex was a predictive risk factor for stroke (HR: 1.42; 95% CI: 1.00-
2.00) but not for major CV events (HR: 1.00; 95% CI: 0.83-1.23)[29].  Kang et al. reported 
data on 10846 newly diagnosed AF patients from the Korean National Health Insurance 
Service[44]. Women represented almost half of the sample, were slightly older, more likely 
to have chronic heart failure or chronic lung disease but history of cerebrovascular 
diseases or ischemic heart diseases were no different compared to men[29]. While it was 
found a significant association between each other CHA2DS2-VASc score items and stroke 
occurrence, there was an inverse association between female sex and stroke (HR: 0.75; 
95% CI: 0.66-0.86)[29]. 
 
3.2 Risk of Bias Evaluation 
Risk of bias evaluation is shown in the Supplementary Material (Table S1). Overall, only 1 
study was considered to be at high risk of bias, while 4 (9.1%) were considered to be at 
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11 
medium risk of bias. All the other studies (40 out of 44) were considered at low risk of bias. 
No publication bias was found for stroke outcome (p=0.39) [Figure S3]. Some small 
publication bias was identified for the other outcomes, even though none reached 
statistical significance [Figure S4-S7]. 
 
3.3 Meta-Analysis of Included Studies 
After extraction, all data were pooled. Data on 993603 AF patients were retrieved from the 
44 studies, with 485933 (48.9%) women and 507670 (51.1%) men. Twenty-six 
studies[12,14–17,19–21,23,24,26,28,29,31–33,35,37,38,40,44,45,47,49,52,55] reported 
data on stroke occurrence, 22 studies[13,18,19,22,23,25,27,30,31,34,36,37,39,41–
43,46,48,50,51,53,54] reported data on TE occurrence, 16 studies[15,36,39,43,46–53] 
reported data on major bleeding, 7 studies[19,27,35,36,39,45,46] reported data on CV 
death and, lastly, 13 studies[19,23,25,33,35,36,38,39,43,45,47,50,52] reported data on all-
cause death. 
 
Pooling of studies results showed that female AF patients were at higher risk of stroke 
compared to male AF patients, with a 24% of relative risk increase (HR: 1.24; 95% CI: 
1.14-1.36; p<0.001) with a moderate heterogeneity (I2= 55.96%) [Figure 1]. No difference 
in TE risk was found in the overall population (HR: 1.08; 95% CI: 0.88-1.32 for female vs. 
male patients) [Figure 1]. Similarly, no difference was found for the occurrence of major 
bleeding, CV death and all-cause death [Figure 1]. A random-effects model was used for 
stroke, TEE, major bleeding and all-cause death [Figure S8-S9-S10-S12], while a fixed-
effects model was used for CV death [Figure S11]. 
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3.4 Meta-Regression Analyses 
We performed meta-regression analysis (Table 2, Panel A) considering the main study 
characteristics (patients’ age, female sex prevalence, OAC use, follow-up time, year of 
issue, type of study and geographic location) and reported HRs and 95% CI for subgroups 
considered (Table 2, Panel B). 
 
3.4.1 a) Continuous Predictors 
We found no differences in pooled HRs in relation to female sex prevalence and follow-up 
time for any outcomes. Conversely, we found a significant increase in HR for stroke 
occurrence in female vs. male patients with progressively increasing age (Delta HR: 1.01; 
95% CI: 1.00-1.03 for each year of increasing age) (Table 2, Panel A).  
 
Looking at the relationship between age and risk of stroke, when comparing female vs. 
male AF patients, the HR for stroke in female vs. male patients progressively increased 
with increasing age [Figure 2, Panel A], becoming significant (and progressively higher) for 
those age ≥65 years old.  
 
Increasing OAC use was associated with a significant reduction in risk for CV death in 
female vs. male patients (Delta HR: 0.26; 95% CI: 0.10-0.66). There was a significantly 
higher risk of CV death for female vs. male patients especially with lower use of OAC, 
while the risk progressively decreased with the increasing use of OAC, becoming non-
significant for an OAC prevalence greater than 42% and reversing when almost all patients 
are treated [Figure 2, Panel B]. 
 
ACCEPTED MANUSCRIPT
AC
C
EP
TE
D
 M
AN
U
SC
R
IP
T
 
 
 
13 
3.4.2 b) Categorical Predictors 
Meta-regression of categorical predictors found no significant influence of year of study 
publication on reported stroke risk (Table 2, Panel A), with an increased risk of stroke for 
female vs. male AF patients in all year subgroups (Table 2, Panel B): 1999-2012 
(p=0.001), 2013-2015 (p=0.008), 2016-2017 (p=0.018).  
 
Examining age according to classes, both age 65-75 years old (p=0.002) and age >75 
years old (p=0.010) significantly increased stroke risk for women vs. men when compared 
to age <65 years old (Table 2, Panel A), with the same age categories reporting a relative 
risk increase of 36% (p<0.001) and 27% (p<0.001), respectively (Table 2, Panel B). 
 
A significant reduction in differential risk for women, compared to men, for major bleeding 
and CV death was found for the studies more recently published (Table 2, Panel A). For 
example, for the studies published in the 1999-2012 subgroup, a higher risk in female AF 
patients was seen for major bleeding (HR: 1.63; 95% CI: 1.03-2.58) and CV death (HR: 
2.08; 95% CI: 1.03-4.23), while no difference was found in papers published in 2013-2015 
and 2016-2017 (Table 2, Panel B).  
While the increased risk of stroke for female patients was non-statistically different across 
the types of study (Table 2, Panel A), subgroup analysis found that for insurance database 
and observational studies, the increase in risk did not reach statistical significance 
(p=0.086 and p=0.148, respectively) (Table 2, Panel B).  
 
Population cohort studies found an increase CV death risk in female vs. male AF patients 
(Delta HR: 5.08; 95% CI: 1.83-14.11) compared to RCTs. The RCTs subgroups had a 
lower risk for female vs. male patients (HR: 0.77; 95% CI: 0.60-0.99), while the population 
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cohort studies subgroup reported a higher risk of CV death for female AF patients (HR: 
3.90; 95% CI: 1.45-10.51). 
 
Geographic location affected the risk of stroke, with a significant reduction in women seen 
for North America (Delta HR: 0.87; 95% CI: 0.79-0.96) and Middle East/Asia (Delta HR: 
0.73; 95% CI: 0.63-0.83) (Table 2, Panel A). The risk of stroke for female vs. male AF 
patients was lower in North America (HR: 1.20; 95% CI: 1.13-1.29) than in Europe (HR: 
1.38; 95% CI: 1.28-1.49) while remaining significantly higher in women, studies in Middle 
East/Asia found no difference in stroke risk between female and male AF patients 
(p=0.895) (Table 2, Panel B), whilst a lower risk for women compared to men for TE 
occurrence in Middle East/Asia was found (p=0.001). Conversely, there was an increased 
risk for TE in female vs. male AF patients for European and Multinational studies (p=0.026 
and p=0.002, respectively).  
 
North America and Multinational studies showed a significant reduction in CV death risk for 
female AF patients (p=0.016 and p=0.004), compared to European studies, that reported 
an increased CV death risk for female vs. male patients (HR: 2.79; 95% CI: 1.21-6.46). 
 
3.5 Sensitivity Analyses 
The increased risk of stroke for female AF patients showed no significant changes when 
each of the studies included were removed sequentially [Figure S13]. For TE occurrence, 
removal from the meta-analysis of the studies by Guo et al. (2013)[23] or by Inoue et al. 
(2014)[27] led to a significantly increased risk for TE in female vs. male AF patients, while 
in all other cases there was no difference in risk [Figure S14].  
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4. DISCUSSION 
This systematic review and meta-analysis extensively analysed sex differences in stroke 
and TE risk amongst patients with AF. Collecting almost one million patients and despite 
the presence of a moderate heterogeneity, we provided evidence about the increased risk 
of stroke in female AF patients compared to men. There was an age dependency to this 
relationship, with significant relationship between increasing age and the increased risk for 
stroke in women compared to men that was most evident at age>65 years.   
  
We did not find any evidence of sex differences in either major bleeding events or all-
cause death, whereas possible sex differences in CV death risk may be mediated by OAC 
therapy, geographic location and type of population examined. As would be expected, we 
found an inverse relationship between the OAC therapy and risk of CV death in female AF 
patients. Further, the meta-regression and subgroup analyses showed that population 
cohort studies demonstrated an increased CV death risk in women, while RCTs suggested 
a reduced risk of CV death in women. We could hypothesise that in “real-life” cohorts, 
compared to RCTs that usually enrol more selected patients, the excess of risk in female 
AF patients could also determine the increased risk for CV death, particularly when not 
modulated by OAC use, which is usually underprescribed in “real-life” cohorts. 
 
Early observational studies suggested that female sex could be a major risk factor for 
stroke and TE [24,35,56]. For example, Fang and colleagues found that female AF 
patients reported a 60% increase in adjusted relative risk for any thromboembolism 
compared to men, particularly in those aged ≥75 years old[56]. Other large nationwide 
studies proved that after full adjustments a strong age-dependency of an increased risk of 
stroke in women remained evident[17]. An analysis derived from the Danish Nationwide 
registries, reported that female sex did not imply an increased risk of stroke itself, but 
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rather increased the risk when added to other major risk factors for stroke and TE[57]. 
These data generated a large debate about the real role of female sex in modulating risk 
of stroke in AF patients, with some researchers suggesting that female sex was a “risk 
modifier” rather than a proper “risk factor” per se[58]. 
 
In this context, our systematic review and meta-analysis provides some robust evidence 
on female sex in conferring a higher stroke risk in AF patients. Furthermore, we clearly 
demonstrated the direct “dose-effect” relationship between age and stroke risk in 
determining the increased risk in women. Our study does not support the notion that the 
lower prevalence of women, actually reported in a large number of the studies included 
could have an influence in confounding the real impact of sex in determining major 
outcomes[59,60].  
 
Lastly, among Asian patients the higher stroke risk ascribed to women was no longer 
evident, while an inverse risk (higher risk in men) appeared for occurrence of TE. Thus, 
race and sex could substantially interact  in determining the stroke/TE risk of Asian AF 
patients[61]. 
 
Regarding TE occurrence, our sensitivity analysis suggests that a higher risk for women 
with AFmay be present. Indeed, alternatively removing from the meta-analysis two 
studies[23,27] led to a significant increased risk for female patients. Considering that the 
two studies shared similar characteristics, meta-analytic results after their exclusion could 
be still externally valid and would imply some evidence of higher TE risk in female AF 
patients.   
 
ACCEPTED MANUSCRIPT
AC
C
EP
TE
D
 M
AN
U
SC
R
IP
T
 
 
 
17 
Several mechanisms have been described to explain the higher thromboembolic risk in 
female patients with AF[62]. Sex-gender differences were reported in arterial structure, 
alterations in blood flow, shear stress and endothelial function[62]. Furthermore, an 
influence of sex has been described in atrial structure and function, which could affect 
atrial thrombogenesis mechanisms[63–65]. Also, gender-related alterations in 
inflammatory and pro-coagulant markers, thrombogenic particles and platelet aggregation 
may play a role [62]. Indeed, hormone replacement therapy has been reported as a 
possible factor playing a role in determining thromboembolic risk, but available data have 
been largely conflicting[3,66]. 
 
In the overall analysis, we found no difference between female and male AF patients for 
CV death. Nevertheless, CV death risk in female patients increased with decreasing OAC 
use in AF patients. Our meta-analysis reinforces the concept that OAC therapy also plays 
a pivotal role in the reduction of CV death risk, especially in women. Indeed, there is an 
inverse association between use of OAC and death risk, with ~35% risk reduction in both 
CV and all-cause death[67]. In a large Spanish cohort, the cessation of OAC therapy was 
associated with an increased risk of all-cause death[68].  The adherence of clinicians to 
guideline recommendations  for OAC therapy is associated with a reduction in all-cause 
death risk[69,70]. These data underline once more the benefits of OAC in AF patients 
regardless of sex, yet a lower OAC prescription rate is constantly reported amongst female 
AF patients[71–73]. 
 
Interestingly, there was evidence of an increased risk of CV death for female AF patients 
in population cohort studies, while an increased risk for CV death in male AF patients is 
present in RCTs. In fact, RCTs disproportionally excluded elderly women with high 
prevalence of co-morbidities while, in the population cohort studies, female patients were 
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usually older than male ones at the baseline, reflecting a more complex clinical status and 
an increased CV risk. Conversely, in the RCTs clinical characteristics were often more 
similar across the patients included regardless sex. 
 
Our results suggest that better assessment of the overall baseline risk in female patients is 
needed, especially amongst the elderly.  Given other evidence suggesting that female 
patients are less appropriately prescribed OAC[10], our results underline the need for 
proper guideline-adherent prescription of OAC independent of sex, with female patients 
appropriately prescribed according to their baseline risk. 
 
4.1 Limitations and Strength 
The main limitation of this meta-analysis is related to the absence of a meta-regression 
analysis according to baseline thromboembolic risk, as defined by CHADS2 or CHA2DS2-
VASc scores. Even though thromboembolic risk was generally higher in female than in 
male AF patients, many of the studies included in the systematic review had no formal risk 
assessment score used, whereas in those where scores were reported there was wide 
heterogeneity in application and definition. Notwithstanding, given the large number of 
patients included in the meta-analysis and the consistency of results reported in the meta-
regression analysis we provided fairly robust conclusions about the increased risk of 
stroke in female AF patients. Moreover, the variability related to type of studies included 
and geographic location further reinforces the strength of our results, extending the 
external validity of this meta-analysis. 
 
5. CONCLUSION 
Women with AF are at increased risk of stroke compared to men. There was an age 
dependency to this relationship, with significant relationship between increasing age and 
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the increased risk for stroke in women compared to men that was most evident at age >65 
years. Some evidence may suggest an increased risk for female AF patients also for TE 
and CV death. Female sex may act as a risk modifier, particularly in elderly AF subjects, 
conferring a significant increase in risk for stroke and major adverse events. 
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Table 1: Baseline Characteristics of Included Studies 
Study Year Cohort Type Location N Age 
(Mean) 
OAC Use FU years 
(Mean) 
Hart[12] 1999 RCT Multinational M: 1449 
W: 563 
NA Overall: 14.4% 2 
Inoue[13] 2000 Multicentre 
Observational 
Study 
United States M: 507 
W: 233 
NA Overall: 9.9% 3.4 
Wang[24] 2003 Population  
Cohort 
United States M: 462 
W: 406 
NA Overall: 18.8% 4.3 
Friberg[35] 2004 Population  
Cohort 
Denmark M: 166 
W: 110 
M: 69.0 
W: 67.0 
Overall: 2.2% 
M: 4.9% 
W: 3.7% 
4.7 
Rienstra[46] 2005 RCT Multinational M: 330 
W: 192 
M: 67 
W: 71 
Overall: 100% 2.3 
Gomberg-Maitland[51] 2006 RCT Multinational M: 5072 
W: 2257 
M: 69.8 
W: 73.4 
Overall: 49.4% 
M: 49.8% 
W: 48.7% 
1.5 
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Dagres[52] 2007 Multicentre 
Observational 
Study 
Europe M: 3084 
W: 2249 
M: 64 
W: 70 
Overall: 65% 1 
Poli[53] 2009 Single Centre 
Observational 
Study 
Italy M: 505 
W: 275 
M: 74 
W: 76 
(Median) 
Overall: 100% 3.1 
Ruigomez[54] 2009 Population  
Cohort 
UK M: 405 
W: 426 
NA NA 3.6 
Lin[55] 2011 Population 
Cohort 
Taiwan M: 4287 
W: 3633 
NA Overall: 0% 4.5 
(Median) 
Van Staa[14] 2011 Population  
Cohort 
UK M: 40140 
W: 39704 
NA Overall: 20.1% 4.0 
Avgil Tsadok[15] 2012 Population  
Cohort 
Canada M: 39398 
W: 44115 
M: 77.2 
W: 80.2 
(Median) 
Overall: 59.5% 
M: 58.2% 
W: 60.6% 
2.8  
Chao[16] 2012 Insurance 
Database 
Taiwan M: 509 
W: 320 
NA Overall: 0% 4.8 
Friberg[17] 2012 Population 
Cohort 
Sweden M: 50135 
W: 50667 
M: 74.7 
W: 80.9 
Overall: 0% 1.2 
(Median) 
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Mikkelsen[18] 2012 Population  
Cohort 
Denmark M: 42458 
W: 44744 
M: 71.0 
W: 78.2 
Overall: 0% 12 
Potpara[19] 2012 Single Centre 
Observational 
Study 
Serbia M: 547 
W: 315 
M: 49.6 
W: 56.7 
Overall: 17.2% 
M: 21.0% 
W: 10.5% 
10 
Sullivan[20] 2012 RCT United States M: 2466 
W: 1584 
M: 68.3 
W: 71.3 
Overall: 77.8% 
M: 76.9% 
W: 79.3% 
3.5 
Bosch[21] 2013 Multicentre 
Observational 
Study 
Germany M: 1721 
W: 1021 
M: 67.5 
W: 71.2 
Overall: 93.8% 
M: 94.1% 
W: 93.4% 
1 
Disertori[22] 2013 Multicentre 
Observational 
Study 
Italy M: 747 
W: 487 
NA Overall: 50.7% 1 
Guo[23] 2013 Single Centre 
Observational 
Study 
China M: 753 
W: 281 
M: 78 
W: 71 
(Median) 
Overall: 14.4% 
M: 13.8% 
W: 16.0% 
1.9 
(Median) 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 
 
 
36 
Poli[25] 2013 Multicentre 
Observational 
Study 
Italy M: 1361 
W: 1654 
M: 82.6 
W: 83.1 
(Median) 
Overall: 100% 2.5 
Aakre[26] 2014 Population  
Cohort 
United States M: 1400 
W: 1320 
NA Overall: 5% 4.37 
Inoue[27] 2014 Multicentre 
Observational 
Study 
Japan M: 5241 
W: 2165 
M: 69 
W: 73 
Overall:86.5% 
M: 86.5% 
W: 86.3% 
2 
Siu[28] 2014 Single Centre 
Observational 
Study 
Hong Kong M: 4663 
W: 5064 
NA Overall: 19.7% 3.19 
Yang[29] 2014 Population  
Cohort 
China M: 911 
W: 1104 
NA Overall: 18.6% 
M: 16.6% 
W: 20.3% 
1 
Avgil Tsadok[30] 2015 Population  
Cohort 
Canada M: 31324 
W: 31786 
M: 76.3 
W: 80.3 
Overall: 74.8% VKA + 25.2% D 
M: 73.4% VKA + 26.6% D 
W: 76.2% VKA + 23.8% D 
1.3 
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Bekwelem[31] 2015 RCTs Multinational M: 23622 
W: 14351 
NA Overall: 24.7% VKA + 31.8% D + 7.4% A 
M: 25.5% VKA + 32.6% D + 7.0% A 
W: 23.5% VKA + 30.6% D + 8.0% A 
2.4 
Chao[32] 2015 Insurance 
Database 
Taiwan M: 22351 
W: 14290 
M: 59.1 
W: 59.1 
Overall: 0% 5.2 
Shantsila[33] 2015 Population  
Cohort 
UK M: 1218 
W: 1041 
M: 73 
W: 79 
Overall: 50% 
M: 52% 
W: 47% 
1 
Tomita[34] 2015 Multicentre 
Observational 
Study 
Japan M: 703 
W: 294 
M: 66 
W: 71 
Overall: 23.4% 
M: 23.9% 
W: 22.4% 
2 
Vinereanu[36] 2015 RCT Multinational M: 11785 
W: 6416 
M: 69 
W: 72 
(Median) 
Overall: 49.9% VKA + 50.1% A 
M: 50.1% VKA + 49.9% A 
W: 49.6 VKA + 50.4% A 
1.8 
Boriani[37] 2016 Multicentre 
Observational 
Study 
Italy M: 1909 
W: 489 
M: 67 
W: 68 
(Median) 
Overall: 23.2% 
M: 23.2% 
W: 23.1% 
3.6 
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Kassim[38] 2016 Single Centre 
Observational 
Study 
United States M: 2537 
W: 1774 
M: 66.8 
W: 72.5 
Overall: 70.6% VKA + 22.7% NOACs 
M: 71.7% VKA + 24.6% NOACs 
W: 69.9% VKA + 19.9% NOACs 
3.3 
Piccini[39] 2016 Multicentre 
Observational 
Study 
United States M: 5842 
W: 4293 
M: 73 
W: 77 
(Median) 
Overall: 71.2% VKA + 4.9% D 
M: 71.2% VKA + 5.0% D 
W: 71.2% VKA + 5.0% D 
2 
Wandell[40] 2016 Population  
Cohort 
Sweden M: 6269 
W: 5248 
M: 71.8 
W: 76.9 
Overall: 48.8% 
M: 52.7% 
W: 44.0% 
5.4 
Xing[41] 2016 Single Centre 
Observational 
Study 
Japan M: 294 
W: 119 
NA Overall: 0% 1.99 
Andersson[42] 2017 Population  
Cohort 
Sweden M: 26977 
W: 21456 
M: 69.5 
W: 74.1 
Overall: 43.9% 
M: 44.8% 
W: 42.8% 
4 
Camm[43] 2017 Multicentre 
Observational 
Study 
Multinational M: 15915 
W: 12709 
M: 67.6 
W: 72.4 
Overall: 46.3% VKA + 17.9% NOACs 
M: 46.0% VKA + 17.9% NOACs 
W: 46.8% VKA + 17.1% NOACs 
1 
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Legend: A= Apixaban; D= Dabigatran; FU= Follow-Up; M= Men; NA= Not Available; OAC= Oral Anticoagulant; R= Rivaroxaban; 
RCT= Randomised Controlled Trial; VKA= Vitamin K Antagonist; W= Women. 
Kang[44] 2017 Population  
Cohort 
Korea M: 5768 
W: 5078 
M: 65.9 
W: 61.8 
Overall: 0% 2.8 
O’Neal[45] 2017 RCT Multinational M: 641 
W: 550 
NA NA 3.4 
(Median) 
Renoux[47] 2017 Insurance 
Database 
Canada M: 71135 
W: 76487 
M: 73.7 
W: 77.1 
Overall: 43% 2.9 
Schnabel[48] 2017 Multicentre 
Observational 
Study 
Europe M: 3866 
W: 2546 
M: 70.1 
W: 74.1 
Overall: 94% 
M: 94% 
W: 94% 
1 
Shanta[49] 2017 Insurance 
Database 
United States M: 65734 
W: 81137 
NA Overall: 69.2% VKA + 15.0% D + 15.8% R 
M: 66.0% VKA + 16.3% D + 17.7% R 
W: 71.9% VKA + 13.8% D + 14.3% R 
1.2 
(Median) 
Shehab[50] 2017 Multicentre 
Observational 
Study 
Middle East M: 1063 
W: 980 
M: 55.1 
W: 58.5 
Overall: 30.7% 
M: 25.1% 
W: 36.8% 
1 
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Table 2: Meta-regression Analysis for Clinical Predictors for Women vs. Men for Outcomes* 
 
 Stroke TEE Major Bleeding CV Death All-Cause Death 
 Delta HR 
(95% CI) 
p Delta HR 
(95% CI) 
p Delta HR 
(95% CI) 
p Delta HR 
(95% CI) 
p Delta HR 
(95% CI) 
p 
A) DIFFERENCES IN POOLED HR ACCORDING TO CONTINUOUS AND CATEGORICAL PREDICTORS 
Continuous Predictors 
Age (years) 1.01 (1.00-1.03) 0.037 1.01 (0.97-1.04) 0.648 0.99 (0.96-1.03) 0.708 0.98 (0.92-1.04) 0.570 1.01 (0.97-1.05) 0.779 
Females (%) 1.00 (0.99-1.01) 0.992 1.02 (0.99-1.05) 0.067 0.99 (0.97-1.02) 0.584 0.99 (0.96-1.04) 0.893 1.03 (0.99-1.07) 0.157 
OAC use (%) 1.03 (0.76-1.39) 0.842 1.67 (0.71-3.95) 0.239 0.78 (0.39-1.58) 0.499 0.26 (0.10-0.66) 0.005 1.09 (0.39-3.01) 0.875 
FU (years) 0.96 (0.91-1.01) 0.138 0.99 (0.93-1.06) 0.907 0.99 (0.84-1.16) 0.864 1.12 (0.95-1.31) 0.171 1.06 (0.90-1.24) 0.486 
Categorical Predictors 
Age classes           
<65 years (ref.) - - - - - - - - - - 
65-75 years 1.38 (1.13-1.70) 0.002 1.22 (0.59-2.50) 0.588 0.85 (0.29-2.50) 0.773 0.74 (0.15-3.61) 0.705 0.71 (0.30-1.66) 0.428 
>75 years 1.29 (1.06-1.57) 0.010 1.33 (0.56-3.14) 0.522 0.77 (0.26-2.25) 0.630 No studies 1.10 (0.43-2.84) 0.842 
Year of Issue           
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1999-2012 (ref.) - - - - - - - - - - 
2013-2015 0.97 (0.79-1.21) 0.806 0.82 (0.49-1.36) 0.437 0.57 (0.34-0.95) 0.032 0.38 (0.18-0.82) 0.014 2.00 (1.04-3.85) 0.038 
2016-2017 0.95 (0.77-1.18) 0.652 1.23 (0.73-2.06) 0.440 0.67 (0.41-1.09) 0.106 0.41 (0.19-0.87) 0.021 2.17 (1.19-3.95) 0.011 
Type of Study           
RCT (ref.) - - - - - - - - - - 
Observational 0.84 (0.60-1.18) 0.305 0.70 (0.46-1.07) 0.097 0.96 (0.63-1.47) 0.132 1.25 (0.83-1.89) 0.290 0.95 (0.49-1.86) 0.882 
Population Cohort 0.88 (0.67-1.15) 0.337 0.89 (0.59-1.35) 0.582 0.70 (0.44-1.11) 0.867 5.08 (1.83-14.11) 0.002 2.01 (0.79-5.12) 0.143 
Insurance DB 0.81 (0.60-1.08) 0.153 No studies 0.89 (0.59-1.33) 0.567 No studies 1.16 (0.44-3.08) 0.763 
Location           
Europe (ref.) - - - - - - - - - - 
North America 0.87 (0.79-0.96) 0.007 1.04 (0.78-1.38) 0.804 0.87 (0.53-1.40) 0.556 0.33 (0.13-0.81) 0.016 1.24 (0.61-2.55) 0.552 
Middle East/Asia 0.73 (0.63-0.83) <0.001 0.42 (0.27-0.65) <0.001 0.79 (0.25-2.43) 0.676 0.49 (0.13-1.84) 0.291 0.79 (0.32-1.96) 0.613 
Multinational 1.01 (0.84-1.23) 0.890 1.14 (0.89-1.46) 0.297 1.00 (0.58-1.73) 0.990 0.27 (0.11-0.66) 0.004 1.09 (0.52-2.22) 0.838 
B) POOLED HR AND 95% CI ACCORDING TO SUBGROUPS 
Age classes           
<65 years 0.98 (0.83-1.16) 0.844 0.89 (0.45-1.74) 0.730 1.35 (0.47-3.85) 0.579 1.20 (0.25-5.81) 0.821 1.04 (0.47-2.30) 0.920 
65-75 years 1.36 (1.21-1.53) <0.001 1.08 (0.84-1.39) 0.528 1.15 (0.91-1.46) 0.252 0.88 (0.73-1.07) 0.215 0.74 (0.53-1.03) 0.070 
>75 years 1.27 (1.15-1.40) <0.001 1.18 (0.69-2.02) 0.552 1.03 (0.83-1.29) 0.769 No studies 1.15 (0.68-1.94) 0.605 
Year of Issue           
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Legend: *Grey Cells and Bold Text Depict Statistically Significant Association; CI= Confidence Interval; CV= Cardiovascular; DB= 
Database; FU= Follow-Up; HR= Hazard Ratio; OAC= Oral Anticoagulant; RCT= Randomized Clinical Trial; TEE= Thromboembolic 
Events. 
1999-2012 1.27 (1.10-1.47) 0.001 1.09 (0.74-1.61) 0.669 1.63 (1.03-2.58) 0.038 2.08 (1.03-4.23) 0.043 0.45 (0.26-0.78) 0.004 
2013-2015 1.24 (1.06-1.45) 0.008 0.89 (0.65-1.23) 0.481 0.94 (0.75-1.16) 0.538 0.79 (0.58,1.08) 0.138 0.90 (0.62-1.31) 0.586 
2016-2017 1.21 (1.03-1.42) 0.018 1.34 (0.95-1.88) 0.096 1.09 (0.92-1.28) 0.330 0.85 (0.65-1.12) 0.254 0.98 (0.76-1.27) 0.876 
Type of Study           
RCT 1.43 (1.12-1.82) 0.004 1.33 (0.97-1.84) 0.081 1.07 (0.85-1.35) 0.542 0.77 (0.60-0.99) 0.041 0.80 (0.47-1.44) 0.457 
Observational 1.19 (0.94-1.52) 0.148 0.94 (0.72-1.22) 0.628 1.17 (0.91-1.50) 0.231 0.96 (0.69-1.33) 0.807 0.76 (0.55-1.06) 0.103 
Population Cohort 1.25 (1.12-1.40) <0.001 1.19 (0.91-1.54) 0.204 0.85 (0.62-1.16) 0.308 3.90 (1.45-10.51) 0.007 1.61 (0.78-3.34) 0.201 
Insurance DB 1.15 (0.98-1.36) 0.086 No studies 1.07 (0.85-1.35) 0.542 No studies 0.93 (0.43-2.03) 0.855 
Location           
Europe 1.38 (1.28-1.49) <0.001 1.19 (1.02-1.38) 0.026 1.20 (0.78-1.84) 0.415 2.79 (1.21-6.46) 0.016 0.81 (0.50-1.33) 0.412 
North America 1.20 (1.13-1.29) <0.001 1.23 (0.97-1.56) 0.087 1.04 (0.84-1.28) 0.742 0.91 (0.64-1.30) 0.601 1.01 (0.60-1.70) 0.965 
Middle East/Asia 1.10 (0.91-1.12) 0.895 0.50 (0.33-0.75) 0.001 0.94 (0.33-2.67) 0.909 1.37 (0.49-3.81) 0.546 0.64 (0.30-1.37) 0.256 
Multinational 1.40 (1.17-1.67) <0.001 1.35 (1.12-1.65) 0.002 1.20 (0.86-1.68) 0.281 0.70 (0.60-0.99) 0.041 0.88 (0.52-1.49) 0.626 
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FIGURES LEGENDS 
 
Figure 1: Pooled Hazard Ratios for Study Outcomes  
Legend: CI= Confidence Intervals; CV= Cardiovascular; HR= Hazard Ratio; TEE= 
Thromboembolic Events. 
 
Figure 2: Meta-regression Analysis According to Continuous Predictors 
Legend: Panel A) Risk of Stroke according to Age: Full Black Line refers to HR, while 
Dashed Black Lines refer to 95% CI. Red Full line refers to Non-significance line; CI= 
Confidence Interval; HR= Hazard Ratio; Panel B) Risk of CV Death according to OAC 
Use: Full Black Line refers to HR, while Dashed Black Lines refer to 95% CI. Red Full line 
refers to Non-significance line; CI= Confidence Interval; CV= Cardiovascular; HR= Hazard 
Ratio; OAC= Oral Anticoagulant.  
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HIGHLIGHTS 
 Sex differences have been in reported in patients with atrial fibrillation (AF) 
 Female AF patients have a significantly higher risk for stroke than male ones 
 Stroke risk in female AF patients is significantly associated with increasing age 
 Data suggest a possibly increased risk for thromboembolic events (TE)  
 A higher risk for cardiovascular (CV) death in females is mediated by OAC use 
 Data are needed to elucidate the role of female sex in TE and CV death in AF 
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